EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy

Michael Gutmann, Martijn Dijkstra, Philipp Salomon, Jamie Cowles, Anja Federa, Dina Baier, Carola Jaunecker, Iemima Semerean, Venla Karvonen, Christine Pirker, Maria Sibilia iD, Dietmar Herndler-Brandstetter und 4 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202514588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Michael Gutmann und 15 weiteren Autor:innen. Beteiligte Einrichtung: Medical University of Vienna, Center for Cancer Research, Vienna, Austria. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunotherapy, Neoplasms, Oxaliplatin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund, Obermann-Mahlke Stiftung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic application of Toll‐like receptor 7/8 (TLR7/8) agonists against cancer is severely limited due to uncontrolled immune activation. In this study, a platinum(IV)‐based prodrug strategy is developed for the systemic administration of a TLR7/8 agonist, selectively activated in the malignant tissue simultaneously with the immunogenic cell death inducer oxaliplatin. Two oxaliplatin(IV)‐based complexes are synthesized comprising the TLR7/8 agonist gardiquimod: Ox‐Gardi‐PEG, containing polyethylene glycol as the second axial ligand, and Ox‐Gardi‐Mal, a maleimide‐bearing derivative to exploit the tumor‐targeting effects of serum albumin. In vitro, cytotoxicity and immune pathway‐inducing potency of Ox‐Gardi‐PEG and Ox‐Gardi‐Mal are diminished under standard cell culture conditions compared to free oxaliplatin and gardiquimod, respectively, and markedly enhanced under reducing conditions, underscoring the activation‐by‐reduction concept. In vivo, Ox‐Gardi‐Mal shows superior and TLR7/8 signaling‐dependent anticancer efficacy and prolongs overall survival of cancer‐bearing mice, while mitigating hematotoxic effects associated with oxaliplatin. Therapy significantly elevates expression of MHC‐I on antigen‐presenting immune cell subsets, increases the frequency of activated plasmacytoid dendritic cells and tumor‐infiltrating CD8 + T cells, as well as depleted primarily immunosuppressive M2 macrophages. These results demonstrate that tumor‐targeted oxaliplatin(IV)‐based prodrugs carrying TLR7/8 agonists offer a potent dual‐release strategy for improved immunochemotherapy, while minimizing excessive immune responses associated with systemic TLR7/8 activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsImmunotherapyNeoplasmsOxaliplatinProdrugsToll-Like Receptor AgonistsAnimalsFemaleHumansMiceCell Line, TumorToll-Like Receptor 7Toll-Like Receptor 8AminoquinolinesImidazoles

Stichwörter der Autor:innen

TLR7/8albumingardiquimodimmunochemotherapymaleimideoxaliplatinplatinum(IV) prodrugstumor‐targeted

Substanzen

Antineoplastic AgentsgardiquimodOxaliplatinProdrugsToll-Like Receptor 7Toll-Like Receptor 8Toll-Like Receptor AgonistsAminoquinolinesImidazoles

Autor:innen und Institutionen

  • Medical University of Vienna, Center for Cancer Research, Vienna, Austria.
  • Comprehensive Cancer Center Vienna, Medical University & General Hospital, Vienna, Austria.
  • Research Cluster "Translational Cancer Therapy Research", Vienna, Austria.
  • University of Vienna, Faculty of Chemistry, Institute of Inorganic Chemistry, Vienna, Austria.
  • University of Vienna, Vienna Doctoral School in Chemistry (DoSChem), Vienna, Austria.

ORCID-Profile: Maria Sibilia, Walter Berger

Förderung

  • Austrian Science Fund
  • Obermann-Mahlke Stiftung

Zitieren

APA

Gutmann, M., Dijkstra, M., Salomon, P., Cowles, J., Federa, A., Baier, D., Jaunecker, C., Semerean, I., Karvonen, V., Pirker, C., Sibilia, M., Herndler-Brandstetter, D., Heffeter, P., Keppler, B. K., Kowol, C. R., & Berger, W. (2026). Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy. Advanced Science. https://doi.org/10.1002/advs.202514588

Vancouver

Gutmann M, Dijkstra M, Salomon P, Cowles J, Federa A, Baier D, et al. Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy. Advanced Science. 2026. doi:10.1002/advs.202514588

BibTeX
@article{Gutmann2026,
  author = {Gutmann, Michael and Dijkstra, Martijn and Salomon, Philipp and Cowles, Jamie and Federa, Anja and Baier, Dina and Jaunecker, Carola and Semerean, Iemima and Karvonen, Venla and Pirker, Christine and Sibilia, Maria and Herndler-Brandstetter, Dietmar and Heffeter, Petra and Keppler, Bernhard K and Kowol, Christian R and Berger, Walter},
  title = {Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202514588}
}
Kostenlos starten →